Format

Send to

Choose Destination
J Cardiovasc Ultrasound. 2018 Mar;26(1):1-25. doi: 10.4250/jcu.2018.26.1.1. Epub 2018 Mar 28.

Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.

Author information

1
Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
2
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
3
Division of Cardiology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
4
Division of Cardiology, Department of Internal Medicine, Busan Paik Hospital, Inje University, Busan, Korea.
5
Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
6
Department of Cardiology, Center for Clinical Specialty, National Cancer Center, Goyang, Korea.
7
Division of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
8
Division of Cardiology, Department of Medicine, Cardiovascular and Stroke Imaging Center, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Abstract

Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment.

KEYWORDS:

Anti-cancer treatment; Cardio-oncology; Cardiovascular toxicity; Echocardiography

Supplemental Content

Full text links

Icon for The Korean Society of Echocardiography Icon for PubMed Central
Loading ...
Support Center